Ganovo
(Danoprevir)Phase 3Small molecule
RocheDanoprevir is used to treat hepatitis C virus (HCV) infection by helping to stop the virus from reproducing in the body, usually given in combination with other antiviral medications.[1] Ganovo is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Ganovo is one of 100 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.
3
Indications
30
Total Trials
0
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Ganovo
RochePhase 3
PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Incivek
Vertex PharmaceuticalsPreclinical
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
SOF/VEL
GileadPreclinical
Keyhole-Limpet Hemocyanin
Bristol-Myers SquibbPreclinical
Pegintron
Merck & Co.Preclinical
Interferon Alfa
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis8 trials
Interaction5 trials
Tics5 trials
Efficacy and Safety3 trials
5 more indications
Chronic Hepatitis C Virus Infection1 trial
Intravenous1 trial
TED1 trial
Tenofovir Disoproxil Fumarate1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Danoprevir. EMBL-EBI & Wellcome Sanger Institute.
- [4]